Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies
Sabine Vogler ()
Additional contact information
Sabine Vogler: Gesundheit Österreich GmbH (GÖG, Austrian Public Health Institute)
Empirica, 2019, vol. 46, issue 3, No 4, 443-469
Abstract The study aimed to explore the priorities of authorities and payers related to policy options for pharmaceutical pricing and reimbursement and to understand the rationale of their preferences. Representatives of competent authorities for pharmaceutical pricing and reimbursement and public payers of the 28 EU Member States were invited to express their preferences of 16 pharmaceutical policy measures in a web-based questionnaire. Replies of 27 respondents from 22 countries were analysed through a Multi-Criteria Decision Analysis, using an outranking method based on the ELECTRE III algorithm. Follow-up focus groups were held with 47 representatives of authorities and payers from 29 countries. Respondents to the online survey highly prioritized the policy objectives of equitable access to medicines and long-term sustainability of the health care system. They considered a transparent reimbursement process based on clear rules, pharmacoeconomic evaluations, generic substitution, value-based pricing and tendering as most appropriate policy options to achieve intended policy aims. Least preferred policy options were discounts and similar arrangements, differential pricing and external price referencing. However, the latter is a commonly used pricing policy, and discount arrangements have also been increasingly used. Participants of the focus groups highlighted limitations of external price referencing, including over-paying due to referencing to official prices instead of actually paid, confidential discounted prices. Given the lack of perceived alternatives policy-makers continue applying existing tools. At the same time, they are searching for new policy options that should be based on the principles of fairness, solidarity and transparency.
Keywords: Medicines; Europe; Pharmaceutical policies; External price referencing; MCDA; Pricing (search for similar items in EconPapers)
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
http://link.springer.com/10.1007/s10663-019-09446-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:kap:empiri:v:46:y:2019:i:3:d:10.1007_s10663-019-09446-5
Ordering information: This journal article can be ordered from
http://www.springer. ... ration/journal/10663
Access Statistics for this article
Empirica is currently edited by Fritz Breuss and Fritz Breuss
More articles in Empirica from Springer, Austrian Institute for Economic Research, Austrian Economic Association Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla ().